A Revolutionary Step Forward: The Promise of Kidney Xenotransplants
In a groundbreaking development, the year 2025 witnessed a significant leap in renal xenotransplantation, bringing us closer to a future where pig kidney transplants could become a clinical reality. This advancement couldn't have come at a more crucial time, given the ongoing shortage of donor organs.
The United States alone has over 100,000 individuals on the national organ transplant waitlist, with nearly 90,000 of them desperately needing a kidney. Tragically, 11 people lose their lives each day while waiting for a kidney that never arrives. These stark statistics highlight the urgent need for innovative solutions.
The current demand for life-saving kidney transplants far outstrips the supply of available kidneys. However, renewed interest and recent progress in xenotransplantation, the transplantation of solid organs across species, offer a glimmer of hope and the potential to revolutionize kidney transplantation.
A Journey of Decades: The Evolution of Xenotransplant Research
While the enthusiasm surrounding renal xenotransplantation peaked in 2025, its history stretches back over half a century. Kidney xenotransplant research gained popularity in the 1960s when investigators explored nonhuman primates as potential kidney donors, but the clinical results were disappointing. It was in the 1990s that pigs emerged as the preferred source, largely due to their anatomical compatibility, availability, and the feasibility of large-scale gene editing.
After decades of dedicated research, a breakthrough occurred in 2021 when several successful transplants of genetically modified pig kidneys into brain-dead humans were conducted at the University of Alabama and NYU Langone Health. Dr. Robert Montgomery, Chair of the Department of Surgery and Director of the NYU Langone Transplant Institute, explained the significance of these transplants, stating, "What really broke the ice was when we started putting these organs into decedents, brain-dead individuals, and were able to follow them for 1 or 2 months, providing reassurance that there was no transmission of pathogens of concern."
Building on this success, in 2024, Massachusetts General Hospital made history by successfully transplanting a genetically edited pig kidney into a living adult with end-stage kidney disease (ESKD). Although the kidney only lasted for two months before the recipient passed away, it marked a significant milestone.
"Xenotransplantation is the most exciting frontier in kidney transplant that we've seen," said Pranav Garimella, Chief Medical Officer of the American Kidney Fund. "While it's not new, this is the first time we've seen substantial improvements in patient outcomes and longevity with these xenotransplanted kidneys."
Major Breakthroughs in 2025
The momentum continued to build in early 2025 when Massachusetts General Hospital successfully completed its second transplant of a genetically edited pig kidney into a living recipient in January. This procedure was conducted under the US Food and Drug Administration's (FDA) Expanded Access Protocol (EAP), which allows patients with life-threatening illnesses to access experimental treatments when no other options are available. The kidney used in this procedure had undergone 69 genomic edits provided by eGenesis.
The recipient, a 66-year-old male, had been on dialysis for over two years due to end-stage kidney disease (EKSD). His journey to a kidney transplant was further complicated by his O-group blood type, which can significantly extend wait times.
Just a few weeks later, the FDA made history again by clearing the first-ever clinical trials of xenokidneys. United Therapeutics' investigational UKidney™ derived from a 10 gene-edited source pig and eGenesis' 69 gene-edited pig kidney were approved for clinical trials. These trials were designed to enroll patients with ESKD who are ineligible for conventional allogeneic kidney transplants for medical reasons or those who have been on the kidney transplant waitlist but are more likely to die or remain untransplanted than receive a deceased donor kidney transplant within 5 years.
Richard Knight, MD, Medical Director of Transplant Diagnostics at Thermo Fisher Scientific, shared his excitement, stating, "I've been in the field for decades, and I remember when I started as a young surgeon in transplantation. Xenotransplantation was a field pursued in the lab using small animals, and the barriers seemed insurmountable. But this year, the progress has been amazing."
How Close Are We to a Clinical Solution?
Despite these remarkable advancements, experts emphasize that xenotransplantation is not yet ready for routine practice. However, Dr. Montgomery notes that early pig kidney xenografts have "worked right out of the box," unlike early primate studies where accelerated rejection was a significant problem.
While immunological concerns regarding the spread of animal-specific diseases among humans persist, there is an unmet need for an immunosuppressive regimen that can prevent rejection without inducing infection in xenotransplanted patients.
Dr. Knight highlighted the progress made in addressing these concerns, stating, "The xenograft barrier is enormous, but they've made tremendous progress. The second big concern is the transmission of viruses from pigs to humans, which can be controlled through careful selection and breeding of these pigs and potentially downregulating these viruses."
Dr. Montgomery added, "This is very complicated stuff. It's not a perfect solution yet. The gene edits and immunosuppression will continue to improve over time."
In addition to safety concerns, the long-term efficacy of these organs remains uncertain. On average, a kidney transplant from a living donor lasts about 15 to 20 years, while a kidney from a deceased donor lasts about 8 to 12 years. Current kidney xenotransplant data only demonstrates the viability of these organs for a few months.
Garimella expressed caution, stating, "Xenotransplantation is still seen as a bridge to transplantation with a human kidney. Whether these kidneys will last 5, 10, 15, or 20 years like human kidneys is unknown."
Both Garimella and Dr. Montgomery drew parallels to the role of left ventricular assist devices (LVAD) in heart transplantation, predicting that xenotransplantation may serve a similar function in kidney transplantation.
"In some cases, it might be a bridge to a transplant, and in others, it could be destination therapy, depending on the organ and how it evolves," Dr. Montgomery explained.
Ethical and Practical Considerations
As xenotransplantation moves closer to frontline use as a potential solution to the organ donor shortage, Garimella emphasized the need to address ethical, regulatory, and logistical challenges on a large scale.
Dr. Knight also questioned the scalability of xenotransplantation, noting that hundreds or thousands of these transplants would need to be performed annually, raising cost concerns.
"We can develop great medical advances, but if they're too expensive, they won't go anywhere," he said. "I'm interested in finding out if this is scalable and economically feasible."
Looking to the Future
The progress made in 2025 represents a turning point, not the finish line. Many in the field are optimistic that xenotransplantation could offer a viable pathway for thousands of patients who currently have no other options.
"Beyond living donor and deceased donation, the only other option is xenotransplantation, and that's what clinicians are most excited about—the potential for a viable path to get more patients transplanted who simply don't have other options," Dr. Knight concluded.
References
Health Resources & Services Administration. Organ Donation Statistics. May 2025. Accessed December 11, 2025. https://www.organdonor.gov/learn/organ-donation-statistics
UNOS. 90,000 people are waiting for a kidney. Here's one way to get them a kidney faster. January 27, 2025. Accessed December 11, 2025. https://unos.org/news/90000-people-are-waiting-for-a-kidney-heres-one-way-to-get-them-a-kidney-faster/
Cooper DKC, Ekser B, Tector AJ. A brief history of clinical xenotransplantation. Int J Surg. 2015;23(Pt B):205-210. doi:10.1016/j.ijsu.2015.06.060
National Kidney Foundation. Breaking Ground in Transplantation: A New Era with Xenotransplantation. May 31, 2024. Accessed December 11, 2025. https://www.kidney.org/news-stories/breaking-ground-transplantation-new-era-xenotransplantation
Brooks A. Second Xenotransplant with Gene-Edited Pig Kidney Performed at Mass General. HCPLive. February 7, 2025. Accessed December 11, 2025. https://www.hcplive.com/view/mass-general-performs-second-xenotransplant-gene-edited-pig-kidney
Brooks A. FDA Clears First Xenotransplant Trial for Gene-Edited Kidneys. HCPLive. February 3, 2025. Accessed December 11, 2025. https://www.hcplive.com/view/fda-clears-first-xenotransplant-trial-gene-edited-kidneys
Deeley M. FDA greenlights first clinical trials for genetically modified pig kidney transplants in humans. American Kidney Fund. February 6, 2025. Accessed December 11, 2025. https://www.kidneyfund.org/article/fda-greenlights-first-clinical-trials-genetically-modified-pig-kidney-transplants-humans
National Kidney Fund. Kidney Transplant. March 15, 2024. Accessed December 11, 2025. https://www.kidney.org/kidney-topics/kidney-transplant
